Recent Share Trading Activities by Novo Nordisk Executives
This announcement highlights the trading activities of Novo Nordisk A/S shares conducted by the company's executives and board members. According to regulatory requirements, these transactions have been disclosed to ensure transparency and compliance with market regulations.
Details about Executive Transactions
The executive involved in this transaction is Ludovic Helfgott, who serves as the Executive Vice President of Novo Nordisk. The company follows stringent protocols to report any transactions carried out by personnel in managerial roles or closely associated individuals.
Transaction Overview
The latest transaction noted is the sale of shares that occurred on August 8, 2025. In total, 12,000 shares were sold at a price of DKK 326.00 per share. This sale represents a significant aggregated volume amounting to DKK 3,912,000.00.
Significance of These Transactions
Such transactions are a vital part of maintaining shareholder trust and market order. By openly reporting these sales, Novo Nordisk demonstrates its commitment to transparency in the financial markets, showcasing adherence to regulations designed to prevent market abuse.
Novo Nordisk’s Commitment to Healthcare Innovation
Beyond financial transactions, Novo Nordisk A/S plays an essential role in global health, particularly in combating chronic diseases such as diabetes. Established in 1923, the company continues to lead in innovative healthcare solutions, striving to enhance patient access to essential medications.
Market Activity and Shareholder Impact
The trading activities of executives also impact market perception and can influence stock performance. With shares listed on Nasdaq Copenhagen (Novo-B) and American Depositary Receipts on the New York Stock Exchange (NVO), global investors keep a close watch on such developments.
Contact Information for Further Queries
For more details concerning these transactions or other inquiries related to Novo Nordisk, the company has provided relevant contact points:
Media Inquiries
Ambre James-Brown
Phone: +45 3079 9289
Email: abmo@novonordisk.com
Investor Relations
Jacob Martin Wiborg Rode
Phone: +45 3075 5956
Email: jrde@novonordisk.com
Frequently Asked Questions
What is the purpose of the share transaction disclosures?
The disclosures serve to provide transparency and uphold trust in the market by ensuring all trading activities by executives are reported.
Who is Ludovic Helfgott?
Ludovic Helfgott is the Executive Vice President of Novo Nordisk, responsible for overseeing significant operational areas within the company.
What was the volume of shares sold in the recent transaction?
A total of 12,000 shares was sold in the recent transaction conducted by the executive.
How does Novo Nordisk ensure compliance with market regulations?
Novo Nordisk adheres to regulatory requirements and regularly reports transactions made by its executives to ensure compliance with market abuse regulations.
What are Novo Nordisk's main focuses?
Novo Nordisk focuses on driving innovation and expanding access to treatments for chronic diseases, particularly diabetes.
